CA2303132A1 - Intranasal formulations containing scopolamine and method of treating motion sickness - Google Patents
Intranasal formulations containing scopolamine and method of treating motion sickness Download PDFInfo
- Publication number
- CA2303132A1 CA2303132A1 CA002303132A CA2303132A CA2303132A1 CA 2303132 A1 CA2303132 A1 CA 2303132A1 CA 002303132 A CA002303132 A CA 002303132A CA 2303132 A CA2303132 A CA 2303132A CA 2303132 A1 CA2303132 A1 CA 2303132A1
- Authority
- CA
- Canada
- Prior art keywords
- formulations containing
- motion sickness
- intranasal
- intranasal formulations
- scopolamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 title abstract 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 title abstract 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 title abstract 2
- 201000003152 motion sickness Diseases 0.000 title abstract 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 title abstract 2
- 229960002646 scopolamine Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000003349 gelling agent Substances 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960004499 scopolamine hydrobromide Drugs 0.000 abstract 1
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 abstract 1
- 230000008673 vomiting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to pharmaceutical formulations containing scopolamine. More particularly, the invention relates to an intranasal gel formulation including scopolamine hydrobromide in a pharmaceutically acceptable carrier, most preferably an intranasal gel, at a pH at or below about 4.0, preferably at or below about 3.5, and a salt concentration below about 200 mM, with the gel solution incorporating polyvinylalcohol as a gelling agent. The intranasal formulations are particularly useful for preventing and/or treating nausea and/or vomiting associated with, for example, motion sickness.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5865197P | 1997-09-11 | 1997-09-11 | |
| US60/058,651 | 1997-09-11 | ||
| PCT/US1998/018953 WO1999012544A1 (en) | 1997-09-11 | 1998-09-11 | Intranasal formulation containing scopolamine and method of treating motion sickness |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2303132A1 true CA2303132A1 (en) | 1999-03-18 |
| CA2303132C CA2303132C (en) | 2002-07-09 |
Family
ID=22018094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002303132A Expired - Fee Related CA2303132C (en) | 1997-09-11 | 1998-09-11 | Intranasal formulations containing scopolamine and method of treating motion sickness |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1027049A4 (en) |
| JP (1) | JP2002516815A (en) |
| AU (1) | AU742878B2 (en) |
| CA (1) | CA2303132C (en) |
| WO (1) | WO1999012544A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6572849B2 (en) * | 2000-09-20 | 2003-06-03 | Lee Shahinian, Jr. | Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications |
| ES2374507T3 (en) | 2006-03-31 | 2012-02-17 | Wako Pure Chemical Industries, Ltd. | PIRAZOL BASED CYANINE COLOR. |
| KR101444712B1 (en) | 2007-01-31 | 2014-09-26 | 와코 쥰야꾸 고교 가부시키가이샤 | Methods for detecting amplification or deletion of genomic DNA fragments |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1164227B (en) * | 1983-05-13 | 1987-04-08 | Angeli Inst Spa | PHARMACEUTICAL COMPOSITION SUITABLE FOR NASAL ADMINISTRATION OF QUATERNARY AMMONIUM SALTS AND ANTICOLINERGIC ACTIVITIES |
| US7765615B2 (en) * | 2007-03-28 | 2010-08-03 | Michael Robert Eastwood | Chest protector in sports medicine |
-
1998
- 1998-09-11 AU AU93850/98A patent/AU742878B2/en not_active Ceased
- 1998-09-11 EP EP98946945A patent/EP1027049A4/en not_active Ceased
- 1998-09-11 WO PCT/US1998/018953 patent/WO1999012544A1/en not_active Application Discontinuation
- 1998-09-11 CA CA002303132A patent/CA2303132C/en not_active Expired - Fee Related
- 1998-09-11 JP JP2000510441A patent/JP2002516815A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1027049A1 (en) | 2000-08-16 |
| AU742878B2 (en) | 2002-01-17 |
| EP1027049A4 (en) | 2001-09-05 |
| JP2002516815A (en) | 2002-06-11 |
| WO1999012544A1 (en) | 1999-03-18 |
| AU9385098A (en) | 1999-03-29 |
| CA2303132C (en) | 2002-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL319833A1 (en) | Compounds and composition for carrying active media | |
| TW376319B (en) | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine | |
| CA2180816A1 (en) | 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients | |
| CA2193337A1 (en) | 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients | |
| MX9705954A (en) | Formulations and methods for reducing skin irritation. | |
| SI0725779T1 (en) | ||
| EP0993831A3 (en) | Compounds and compositions for delivering active agents | |
| HUP9700005A3 (en) | 2-ureido-benzamide derivatives and pharmaceutical compositions containing them as active agent | |
| CA2234231A1 (en) | Stabilizing formulation for ngf | |
| IL111252A0 (en) | Dihalopropene compound, insecticide/acaricide containing said dihalopropene compound as active ingredient,and intermediate compound for use in production of said dihalopropene compound | |
| CA2163197A1 (en) | Tri(platinum) complexes | |
| ZA934037B (en) | Novel biologically active eburnamenine derivatives, pharmaceutical compositions containing them and process for preparing same. | |
| HUP9901260A3 (en) | Optically active phenylpyrimidine derivative as analgesic agent, process for producing it, pharmaceutical composition containing it and its intermediate | |
| EP0610698A3 (en) | Substituted imidazo(4,5-b)pyridines and benzimidazoles as angiotensin ii antagonistes. | |
| HU906967D0 (en) | Fungicide preparatives containing new amino acid amine derivatives as active substance and process for producing the active substances | |
| CA2303132A1 (en) | Intranasal formulations containing scopolamine and method of treating motion sickness | |
| PT964865E (en) | PHARMACEUTICALLY ACTIVE TRICYLIC ACID AMINE | |
| HU9402648D0 (en) | 3,4-dioxo-1-cyclobuten-1-yl-substituted (indolyl-alkyl)-pyridine- and -pyrimidine derivatives and antimigraine composition containing them as active componens | |
| AU9080398A (en) | Novel diamine alkylene diacetic or triacetic acid derivatives, preparation method, use in cosmetic and pharmaceutical compositions and compositions containing them | |
| HUP0103623A3 (en) | Bispiperidines as antithrombotic agents, their process for preparation and medicament containing them as active ingredient | |
| MX9703839A (en) | Lubeluzole intravenous solutions. | |
| RU97112901A (en) | THROMBOLYTIC PRODUCTS | |
| HU9301958D0 (en) | Method for producing stable pharmaceutical preparatives containing dipeptide derivatives as active agent | |
| TW333453B (en) | Pharmaceutical composition comprising toremifene for use in the treatment of autoimmune diseases | |
| HUT70840A (en) | 2,2-dialkyl-2h-1-benzopiran and 2,2-dialkil-3,4-dihydro-3-hydroxy-2h-1-benzo-pyran derivatives, process for preparing them and pharmaceutical compositions comprising them as an active agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |